376 related articles for article (PubMed ID: 31648477)
1. [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].
Gong JJ; Yin QS; Li MJ; Ai H; Wang Q; Chen L; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):750-754. PubMed ID: 31648477
[No Abstract] [Full Text] [Related]
2. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Gauthier J; Hirayama AV; Purushe J; Hay KA; Lymp J; Li DH; Yeung CCS; Sheih A; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Shadman M; Riddell SR; Maloney DG; Turtle CJ
Blood; 2020 May; 135(19):1650-1660. PubMed ID: 32076701
[TBL] [Abstract][Full Text] [Related]
5. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
[TBL] [Abstract][Full Text] [Related]
7. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
8. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
9. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
Gill S; Vides V; Frey NV; Hexner EO; Metzger S; O'Brien M; Hwang WT; Brogdon JL; Davis MM; Fraietta JA; Gaymon AL; Gladney WL; Lacey SF; Lamontagne A; Mato AR; Maus MV; Melenhorst JJ; Pequignot E; Ruella M; Shestov M; Byrd JC; Schuster SJ; Siegel DL; Levine BL; June CH; Porter DL
Blood Adv; 2022 Nov; 6(21):5774-5785. PubMed ID: 35349631
[TBL] [Abstract][Full Text] [Related]
13. A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
Mato AR; Tang B; Azmi S; Yang K; Zhang X; Stern JC; Hedrick E; Huang J; Sharman JP
Haematologica; 2022 Nov; 107(11):2630-2640. PubMed ID: 35443563
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
[TBL] [Abstract][Full Text] [Related]
15. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
Aw A; Brown JR
Leuk Lymphoma; 2017 Oct; 58(10):2287-2297. PubMed ID: 28482721
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Deeks ED
Drugs; 2017 Feb; 77(2):225-236. PubMed ID: 28105602
[TBL] [Abstract][Full Text] [Related]
17. SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
Burke JM
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):427-435. PubMed ID: 35577753
[TBL] [Abstract][Full Text] [Related]
18. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib in CLL/SLL: From bench to bedside (Review).
Zi F; Yu L; Shi Q; Tang A; Cheng J
Oncol Rep; 2019 Dec; 42(6):2213-2227. PubMed ID: 31638169
[TBL] [Abstract][Full Text] [Related]
20. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
[Next] [New Search]